| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.018 | 0.9 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |